Dr. Chu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 2002 - 2004
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1996 - 1999
University of Rochester School of Medicine and DentistryClass of 1996
Certifications & Licensure
MD State Medical License 2003 - 2026
Publications & Presentations
PubMed
- 280 citationsPhase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Brea...Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia Bianchi, Janice Lu
Journal of Clinical Oncology. 2013-02-04 - 71 citationsMitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modelingIraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Liping L. Sun
NPJ Systems Biology and Applications. 2020-08-28 - 65 citationsDCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall C. Dere, MaryAnn Go
Molecular Cancer Therapeutics. 2013-04-18
Abstracts/Posters
- Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphomaBachanova V, Ghobadi A, Patel K, Park JH, Flinn IW, Shah P, Wong C, Bickers C, Szabo P, Wong L, Valamehr B, Atwal S, Chu YW, Elstrom R and Strati P, 2021 American Society of Hematology Annual Meeting, Atlanta, 11/5/2021
- Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL): Interim safety and effi...Budde LE, Sehn LH, Assouline S, Flinn IW, Isfufi I, Yoon S-S, Kim W-S, Matasar MJ, Nastoupil LJ, Santiago R, Koh Y, Hernandez G, Li C-C, Kulkarni PR, McCall B, McClell..., 2018 American Society of Hematology Annual Meeting, Atlanta, GA USA, 11/29/2018
Press Mentions
Fate Therapeutics Appoints Wayne Chu, M.D. As Vice President, Clinical DevelopmentApril 18th, 2019
Research History
- Senior Research FellowExperimental Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH2002 - 2004
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- American Society for Transplantation and Cellular Therapy - ASTCTMember
Industry Relationships
- Chief Medical Officer, Fate TherapeuticsClinical DevelopmentDisclosure: Full-time employee, stockholder2019 - Present
- Employee, Genentech/RocheGroup Medical Director, Product Development OncologyDisclosure: Full-time employee, Stockholder2009 - 2019
External Links
- LinkedInhttp://www.linkedin.com/in/yuwayechu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
